CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2023-- 2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today that it has commenced an underwritten public
Abecma more than tripled progression-free survival (13.3 months vs. 4.4 months) compared with standard regimens for triple-class exposed multiple myeloma Safety results were consistent with the well-established and predictable safety profile of Abecma Abecma is the first and only CAR T cell
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 1, 2023-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: Guggenheim Oncology Conference 2023, fireside chat on February 9 at 9:00am ET , the St.
Anticipate $470-$570M topline U.S. revenue Abecma (idecabtagene vicleucel) in 2023, shared equally with Bristol Myers Squibb (BMS) KarMMa-3 data to be presented at EBMT-EHA 5 th European CAR T-cell Meeting on February 10, 2023 ; 3L+ sBLA submission for Abecma targeted completion in Q1 Expanded
Collaboration Leverages 2seventy's Platform for T Cell Therapy Research and Development with Regeneron Antibodies and Bispecifics to Explore Multiplex Combination Approaches Regeneron Investing $20 million in 2seventy Equity; Regeneron to Fund 100% of Clinical Development Costs for Regeneron-Based
